Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
siRNA
Biotech
AbbVie tosses ADARx $335M for siRNA options deal
The deal stretches across neuroscience, immunology and oncology and gives ADARx the chance to make “several billion dollars” in additional biobucks.
Zoey Becker
May 14, 2025 9:00am
Atalanta’s RNA epilepsy asset suppresses seizures in mice
Apr 10, 2025 5:30am
Lilly links lepodisiran to durably lower lipoprotein in phase 2
Mar 31, 2025 4:24am
Atalanta loads crossbow with $97M, 2 Big Pharmas in tow
Jan 28, 2025 7:00am
AI-powered Insitro taps Lilly to clear path to clinic for siRNA
Oct 9, 2024 9:28am
Silence breaks down phase 1 data on blood disorder prospect
Jun 27, 2024 9:40am
